PBAC's latest decision on Tsp (tamarindus indica seed polysaccharide): Recommended with restriction (2007). Considered for Severe dry eye syndrome in a patient who is sensitive to preservatives in multi dose eye drops.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2007
Submissions
1
2007 → 2007
Eligible population
Severe dry eye syndrome in a patient who is sensitive to preservatives in multi dose eye drops.
Therapy area
Ophthalmology
Evidence base
Other
Key trials
Bonci e et al, Bux AV et al, Lindsay B. et al, Mannucci LL. et al
Comparator
carmellose sodium eye drops (Cellufresh®) 5 mg per ml, single dose units
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis. No efficacy superiority claimed; no economic evaluation undertaken.